GlassScriptPhysician profile
Jeanette Tan
NPI 1518938810
$204,669.51
in general payments reported to CMS, 2019-2025
33 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $14K · 2021: $58K · 2022: $35K · 2023: $46K · 2024: $26K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Food and Beverage: $6,401 · Travel and Lodging: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,645.00 |
| Food and Beverage | $6,400.91 |
| Travel and Lodging | $1,091.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $135,594.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $65,579.00 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Actelion Pharmaceuticals US, INC. | $365.64 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $361.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.17 | 2020-2025 | Ofev, Jascayd |
| Insmed, INC. | $274.09 | 2024-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $236.44 | 2019-2024 | Yupelri |
| Viiv Healthcare Company | $235.34 | 2019-2021 | |
| Janssen Biotech, INC. | $222.79 | 2022-2023 | Symtuza |
| Jazz Pharmaceuticals INC. | $167.37 | 2020-2024 | |
| Ars Pharmaceuticals Operations, INC. | $143.74 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $134.39 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $121.19 | 2019-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $117.19 | 2025 | Acthar |
| Theratechnologies INC. | $116.70 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $104.27 | 2020-2021 | |
| Emd Serono, INC. | $71.20 | 2020-2021 | |
| Abbott Laboratories | $63.59 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $60.71 | 2020 | |
| Viatris Specialty LLC | $56.30 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $45.08 | 2020-2021 | |
| Novo Nordisk INC | $44.39 | 2019-2020 | |
| Grifols USA, LLC | $33.77 | 2022 | |
| Philips North America LLC | $33.71 | 2019-2025 | Patient Interface Software |
| Abbvie INC. | $29.71 | 2022 | |
| Genentech USA, INC. | $29.09 | 2019 | |
| Csl Behring | $24.68 | 2023 | Hizentra, Privigen |
| Verona Pharma, INC. | $23.24 | 2025 | Ohtuvayre |
| Genzyme Corporation | $19.74 | 2020 | |
| Baxter Healthcare | $18.16 | 2022 | |
| Melinta Therapeutics, LLC | $17.56 | 2020 | |
| United Therapeutics Corporation | $14.40 | 2024 | Tyvaso |
| Gilead Sciences, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.